Analysis

X4 Pharmaceuticals, Inc. (XFOR) Stock Analysis

X4 Pharmaceuticals, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to XFOR.

websiteXFOR/analysis/XFOR

X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to XFOR.

Stock profile

Ticker

XFOR

Asset type

Stock

Market cap

$398.0M

Sector

Health Technology

Industry

Biotechnology

Currency

USD

Ticker listings

X4 Pharmaceuticals, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • XFOR primary listing
  • 48Q0
  • A3E4QR

Latest X4 Pharmaceuticals, Inc. news

X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026 - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the F...

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patient...

- European Commercialization will be Led by X4 Pharmaceuticals’ Partner, Norgine - - Global, Pivotal Phase 3 Clinical Trial Ongoing to Evaluate Mavorixafor in Chronic Neutropeni...

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 - - Positive Opinion from European Medicines Agency Recommending Marketing Authorizat...

X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced t...

Research sections

Valuation

Review valuation context for X4 Pharmaceuticals, Inc..

Future growth

Review future growth context for X4 Pharmaceuticals, Inc..

Past performance

Review past performance context for X4 Pharmaceuticals, Inc..

Financial health

Review financial health context for X4 Pharmaceuticals, Inc..

Dividend

Review dividend context for X4 Pharmaceuticals, Inc..

Management

Review management context for X4 Pharmaceuticals, Inc..

Ownership

Review ownership context for X4 Pharmaceuticals, Inc..

Other information

Review other information context for X4 Pharmaceuticals, Inc..

Community

Review community context for X4 Pharmaceuticals, Inc..